AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626

Reuters03-19 19:00

AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626

AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.
PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.
The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.
The first-in-human Phase 1 trial (NCT06891716) is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.
Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700OMX_____CNEWS_EN_GNW1001171040_en) on March 19, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2620410102?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-19 19:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620410102","market":"us","top_or_hot":-1,"title":"AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.\n        </li>\n<li>\n          PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.\n        </li>\n<li>\n          The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.\n        </li>\n<li>\n          The first-in-human Phase 1 trial (NCT06891716) is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.\n        </li>\n<li>\n          Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700OMX_____CNEWS_EN_GNW1001171040_en) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-19 19:00</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.\n        </li>\n<li>\n          PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.\n        </li>\n<li>\n          The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.\n        </li>\n<li>\n          The first-in-human Phase 1 trial (NCT06891716) is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.\n        </li>\n<li>\n          Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700OMX_____CNEWS_EN_GNW1001171040_en) on March 19, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999014013.SGD","symbol_name":"United Global Durable Equities Fund Dis SGD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260319:nNDL1L9bvR:1","article_id":"2620410102","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620410102","pubTimestamp":1773918035,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.The first-in-human Phase 1 trial  is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","BK4112":"金融交易所和数据","NDAQ":"纳斯达克OMX交易所","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","ACIU":"AC Immune SA","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","BK4585":"ETF&股票定投概念","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","BK4139":"生物科技","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC"},"translate_title":"AC Immune报告TDP-43 PET示踪剂ACI-19626的1期体内脑成像数据","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ACIU":0.9,"NDAQ":0.9},"content_text":"AC Immune reports Phase 1 in vivo brain imaging data for TDP-43 PET tracer ACI-19626\n    \n\n\n          AC Immune reported Phase 1 data for the PET tracer ACI-19626, including in vivo brain images of TDP-43 pathology, which were presented at AD/PD 2026.\n        \n\n          PET scans showed significantly higher ACI-19626 tracer uptake in key brain regions in patients with genetically defined frontotemporal dementia due to C9orf72 mutation than in healthy subjects.\n        \n\n          The company said ACI-19626 demonstrated good safety and tolerability, along with rapid brain uptake and washout consistent with a pharmacokinetic profile for human brain imaging.\n        \n\n          The first-in-human Phase 1 trial (NCT06891716) is being conducted in two parts, with Part 1 in healthy volunteers and genetic FTD expected to be completed in H1 2026.\n        \n\n          Part 2 expansion may include up to 30 patients with FTD, ALS, or LATE, and exploration in additional patient populations including ALS is ongoing.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AC Immune Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603190700OMX_____CNEWS_EN_GNW1001171040_en) on March 19, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.37.0","shortVersion":"4.37.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620410102","isCrawlerRequest":true}